These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 11258429)

  • 1. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil.
    Ringe B; Braun F; Schütz E; Füzesi L; Lorf T; Canelo R; Oellerich M; Ramadori G
    Transplantation; 2001 Feb; 71(4):508-15. PubMed ID: 11258429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation.
    Reggiani P; Arru M; Regazzi M; Gatti S; Molinaro MD; Caccamo L; Maggi U; Melada E; Paone G; Rossi G
    Transplant Proc; 2005 May; 37(4):1697-9. PubMed ID: 15919435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.
    Figueras J; Prieto M; Bernardos A; Rimola A; Suárez F; de Urbina JO; Cuervas-Mons V; Mata Mde L
    Transpl Int; 2006 Aug; 19(8):641-8. PubMed ID: 16827681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation.
    Castedal M; Skoglund C; Axelson C; Bennet W
    Scand J Gastroenterol; 2018 Jun; 53(6):741-747. PubMed ID: 29688072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression.
    Ringe B; Braun F; Wietzke P; Oellerich M; Ramadori G
    Transplant Proc; 2000 Nov; 32(7):2543. PubMed ID: 11120285
    [No Abstract]   [Full Text] [Related]  

  • 6. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
    Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
    Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
    Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients.
    Roth D; Colona J; Burke GW; Ciancio G; Esquenazi V; Miller J
    Transplantation; 1998 Jan; 65(2):248-52. PubMed ID: 9458023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
    Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
    Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
    Boillot O; Seket B; Dumortier J; Pittau G; Boucaud C; Bouffard Y; Scoazec JY
    Liver Transpl; 2009 Nov; 15(11):1426-34. PubMed ID: 19877264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report.
    Jain AB; Hamad I; Rakela J; Dodson F; Kramer D; Demetris J; McMichael J; Starzl TE; Fung JJ
    Transplantation; 1998 Nov; 66(10):1395-8. PubMed ID: 9846530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
    Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
    Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of tacrolimus and mycophenolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation.
    Ciancio G; Lo Monte A; Buscemi G; Miller J; Burke GW
    Transpl Int; 2000; 13 Suppl 1():S191-4. PubMed ID: 11111994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
    Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
    JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
    Miller J; Mendez R; Pirsch JD; Jensik SC
    Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
    Krämer BK; Krüger B; Mack M; Obed A; Banas B; Paczek L; Schlitt HJ
    Transplant Proc; 2005 May; 37(4):1789-91. PubMed ID: 15919467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy.
    Eason JD; Nair S; Cohen AJ; Blazek JL; Loss GE
    Transplantation; 2003 Apr; 75(8):1396-9. PubMed ID: 12717237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.